RxDoctor Payments Data

Raleigh Rumley, DO

Family Medicine · Myrtle Beach, SCNPI 1871971168

Payments from drug & device makers

$1,131in general payments, 2019–2025

Across 29 payments — averaging $39.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$242
  • AstraZeneca$241
  • Abbott$143
  • Novo Nordisk$132
  • Indivior Inc.$86
  • AbbVie$82
  • plus $206 from 5 others

What the payments were for

  • Food & beverage$1,131100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC5$242
AstraZeneca4$241
Abbott1$143
Novo Nordisk2$132
Indivior Inc.1$86
AbbVie(2 entities)4$82
Pfizer4$68
Amarin Pharma, Inc.3$59
GSK3$48
Sanofi Pasteur Inc.1$16
VBI Vaccine (delaware) Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,131 in reported general payments places this provider in the 60th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$72,795
Medicare patients
214
Services billed
1,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide45$51,782
EliquisApixaban30$33,909
JardianceEmpagliflozin22$25,160
XareltoRivaroxaban16$24,877
PercocetOxycodone Hcl/Acetaminophen13$15,636
MounjaroTirzepatide13$13,859
OxycontinOxycodone Hcl13$11,703
Tresiba Flextouch U-100Insulin Degludec11$4,918
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,389
Atorvastatin Calcium191$2,471
Gabapentin115$1,568
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic18$1,552
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$1,387
Albuterol Sulfate HfaAlbuterol Sulfate49$1,370
Sucralfate23$1,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$132$51,78245 claims
PfizerEliquis$68$33,90930 claims
Lilly USA, LLCMounjaro$242$13,85913 claims
AbbVieSynthroid$82$94513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →